CEO sells 3.1M shares in underwritten secondary offering, company receives no proceeds

SBC Medical Group Holdings Inc

Selling stockholder CEO Yoshiyuki Aikawa offered 3,100,000 common shares; underwriters have 45-day option for additional 465,000 shares.
Company did not sell any shares and received no proceeds from the offering.
Underwriting agreement with Maxim Group LLC as representative filed as Exhibit 1.1.
Offering closed on April 21, 2026.
Shares registered on Form S-3 (File No. 333-292451) filed December 29, 2025.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SBC Medical Group Holdings Inc entered into Underwriting Agreement with Maxim Group LLC (effective 2026-04-19).

Action: entry
Agreement: underwriting
Counterparty: Maxim Group LLC
Effective: 2026-04-19

Exact text from the filing

On April 19, 2026, SBC Medical Group Holdings Incorporated (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) by and among the Company, Dr. Yoshiyuki Aikawa, the Company’s CEO and Chairman of the board of directors, as selling stockholder (the “Selling Stockholder”) and Maxim Group LLC, as representative of the several underwriters named in Schedule 1 thereto (the “Underwriters”), relating to an underwritten offering of 3,100,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share, pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-292451), filed on December 29, 2025.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

SBC Medical Group Holdings Inc filing history →

Source: SEC EDGAR

accession 0001493152-26-018603

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.